Tsukamoto, Kazuhisa

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017

Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 813

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., et al. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 313

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., et al. (2026) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 57

Isoform-Dependent Cholesterol Efflux From Macrophages by Apolipoprotein E Is Modulated by Cell Surface Proteoglycans

Hara, M., Matsushima, T., Satoh, H., Iso-o, N., Noto, H., Togo, M., Kimura, S., Hashimoto, Y., & Tsukamoto, K. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 53

Control Status of Atherosclerotic Cardiovascular Risk Factors Among Japanese High-Risk Subjects:Analyses of a Japanese Health Check Database from 2008 to 2011

Hasegawa, K., Tsukamoto, K., Kunimi, M., Asahi, K., Iseki, K., Moriyama, T., Yamagata, K., Tsuruya, K., Fujimoto, S., Narita, I., et al. (2016) · Journal of Atherosclerosis and Thrombosis

Health Promotion and Cardiovascular PreventionDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 10